tested in a highly successful IVF programme having ongoing 0.02 mg leuprolide acetate, administered twice daily by s.c. injection (Ͼ20 weeks) pregnancy rates that routinely exceed 50%.
beginning on cycle day 3, following 2-4 weeks of oral contraceptive use. On cycle day 5, HMG or recombinant FSH treatment was initiated at the dose of 600 IU/day, while continuing leuprolide
Materials and methods
acetate. The remainder of the microflare protocol was similar to that Patient selection of the standardized protocol, which is routinely used in our practice. Study participation was offered to women who were undergoing IVF The frequency in which the microflare protocol was employed was at the Colorado Center for Reproductive Medicine during a period similar (Ͻ10%) in both control groups. of 15 months (July 1997 to October 1998 . For practical reasons, study participation was limited to women living in the geographical Luteal support vicinity of the programme. Patients were not eligible for inclusion in Luteal support was initiated 2 days after oocyte retrieval irrespective the study if they had a history of dysfunctional uterine bleeding, of whether this was provided from the vaginal gel or i.m. injections. current urogenital disease, or previous allergic response to a product
In the vaginal progesterone gel study group, 43 women undergoing containing progesterone. In addition, patients were not permitted to IVF cycles applied single daily doses of Crinone 8%. In either case, use any product containing progesterone or another progestin during luteal support was continued until the pregnancy test was performed the IVF treatment cycle. Patients were only allowed to receive one and for up to 12 weeks in case of pregnancy. The 46 other infertile study treatment cycle. Thus, patients who had been previously enrolled women undergoing concurrent IVF cycles who served as a control would be excluded from participating in the study during a subsequent group received luteal support from daily i.m. injections of progesterone IVF cycle. All patients provided written consent after having been (50 mg). duly informed of possible risks. The study protocol and informed consent form were reviewed and approved by an independent InstituDetermination of pregnancy status tional Review Board (IRB).
Results from this group were compared with: (i) a group of control Pregnancy status was determined by serum β-HCG concentration patients obtained by identifying 46 consecutive IVF patients who approximately 2 weeks after embryo transfer (total PR), by ultrasounds were enrolled beginning October 1997, had satisfied similar 2-4 weeks later (clinical PR), and by counting live births. Biochemical inclusion criteria, but had received luteal support from i.m. progesterpregnancy wastage was defined as any β-HCG value Ͼ5 mIU/ml one (50 mg/day); and (ii) historical IVF data reported for 1996 to that did not evolve into a clinical pregnancy [i.e. biochemical (total the Society for Assisted Reproduction Therapy (SART) (CDC, 1998) were assessed by reference to the number of embryo transfers, as by design the study compared two forms of luteal support which possibly This was an open-label trial designed to assess efficacy and tolerability affected embryo implantation. of the vaginal progesterone gel, Crinone 8%. A group of subjects (n ϭ 43) was recruited to receive Crinone 8%, and the results were compared with those of two control groups. One comparison group Patient acceptability consisted of a similar size sample of women (n ϭ 46) undergoing The acceptability of vaginal progesterone gel was assessed using a IVF concurrently but receiving luteal support from progesterone patient questionnaire that was completed by each subject after their supplied by i.m. injections (50 mg/day), while the second was based last administration of Crinone 8%. Subjects were asked to rank their upon historical data from 1996 reported to SART (CDC, 1998) .
overall experience with the use of Crinone 8% on degree of difficulty of administration, messiness, presence of pain and interference with Stimulation protocols intercourse. A scale of 1 (very much) to 7 (not at all) was used to Study participants received ovarian stimulation according to a standassess the subject's overall experience with the use of Crinone 8% ardized protocol involving luteal phase gonadotrophin-releasing horin regard to these factors. In addition, subjects who had previously mone (GnRH) agonist down-regulation. In accordance with this used other formulations were asked to rank their experience with the protocol, 0.5 mg of leuprolide acetate (Lupron ® ; TAP Pharmaceutical use of Crinone 8% versus the use of progesterone given by injection Inc., Deerfield, IL, USA), administered daily by s.c. injection, was or suppository: easier to use, less painful, takes less time to administer initiated during the luteal phase. This dose was continued until ovarian and preferred method. A scale of 1 (strongly agree) to 7 (strongly suppression was achieved, as confirmed by oestradiol concentrations disagree) was used to assess how each subject's overall experience and sonography. This dose was reduced by one-half with the onset with Crinone 8% compared with other previously used progesterone of ovarian stimulation and continued until human chorionic gonadoformulations on these aspects of treatment. trophin (HCG) administration. Ovarian stimulation was initiated using human menopausal gonadotrophin (HMG) or recombinant FSH. The Statistical analysis typical starting dose was set at 225 to 450 IU/day for 5 days, based
Although the study was not designed to determine equivalence on prior responses to HMG and/or basal FSH values. Further dosing between i.m. progesterone and Crinone 8%, statistical testing was adjustments were based on ultrasound findings and plasma hormone done as a descriptive analysis. Comparable results in the Crinone concentrations, as previously described (Schoolcraft et al., 1991;  8% and both control groups would be considered supportive for Meldrum, 1992 Meldrum, , 1996 . Briefly, when at least two follicles were ജ18 demonstrating efficacy of Crinone 8%. mm in diameter, 10 000 IU of HCG (Profasi ® ; Serono Laboratories, The three groups of IVF patients were compared using Student's Inc., Randolph, MA, USA) were administered. Oocyte retrieval was t-test or Fisher's exact test, with two-tailed comparisons, or Wilcoxon performed 35 to 36 h after HCG administration.
rank sum test, with one-tailed comparisons. χ 2 statistics were used Less than 10% of the patients designated as poor responders were administered a different ovulation stimulation treatment known as to analyse discontinuous data. Overall, acceptability of Crinone 8% when used daily for control groups are summarized in Table I . All patient demoluteal support in IVF was excellent (see Table III ). Of the 43 graphic parameters were similar for both groups of IVF women who responded to the questionnaire, 55.8% had no patients. Regarding IVF characteristics, there were no clinically difficulty administering the gel. For 46.5% of the women, the significant differences between the two groups, although the gel did not at all interfere with intercourse. number of prior IVF attempts was statistically significantly Most of the women who responded to the questionnaire and greater for the Crinone group (P Ͻ 0.001), and days of had previously used i.m. injections agreed that the gel was gonadotrophin stimulation were also slightly higher (P ϭ easier to use (9/13 or 69.2%), less painful (10/13; 76.9%) and 0.027). Baseline early follicular phase FSH concentrations less time-consuming (8/13; 61.5%). Furthermore, a majority were similar at 7.9 Ϯ 2.4 and 8.3 Ϯ 2.8 mIU/ml for the (10/13; 76.9%) of these women strongly agreed that they Crinone group and i.m. progesterone group respectively. There preferred treatment with the vaginal gel to i.m. injections. was no difference in the number of embryos transferred for Women who responded to this questionnaire and had previthese two groups of IVF patients.
ously used progesterone suppositories agreed that the gel was Total (biochemical) pregnancy rates achieved in women easier to use (13/18; 72.2%), less painful (9/18; 50%) and less receiving Crinone (72.1%) were similar to those seen in the time-consuming (11/18; 61.1%). Furthermore, a majority (15/ i.m. group (73.9%) (NS). Clinical pregnancy rate and live 18; 83.3%) of these women agreed that they preferred treatment births rate in the two concurrent IVF groups and the historical with the vaginal gel compared with suppositories. data reported to SART are shown in Table II . The Crinone and i.m. IVF groups respectively were similar for clinical pregnancy rate at 60.5% (26/43) versus 60.9% (28/46); and Discussion for live birth rate 53.5% (23/43) versus 50% (23/46). Live birth rate in the Crinone group (53.5%) was similar to the When using luteal support provided by Crinone 8%, the historical results reported to SART for the younger two age pregnancy rates obtained in this study were comparable with groups (57.7% for women aged Ͻ35 and 51.7% for women results routinely achieved at our institution over the past years aged 35-39 years). Comparing the Crinone 8% group, whose (CDC, 1998) . In 43 women receiving Crinone 8%, total PR, mean age was 36.2 Ϯ 4.5 years, to the comparable age group clinical PR and live birth rates were 72.1 and 60.5 and reported to SART actually suggested a trend towards improved 53.5% per embryo transfer respectively. To provide a current results (53.5 versus 51.7% for Crinone and historical data comparison, we examined the results of 46 consecutive women respectively).
undergoing IVF at our centre who received luteal support from The rates of biochemical pregnancies (n) and total pregnancy i.m. progesterone during the same period. There were no clinically significant differences between the IVF characterwastage (n) were also similar for the Crinone and concurrent rates were found when luteal support was provided either with gel (Jobanputra et al., 1999) reliably resulted in in-phase endometrial biopsies and pregnancy rates similar to those seen istics of women receiving vaginal and i.m. progesterone when luteal support was provided by i.m. injections. The fact (controls). In the Crinone group, the mean number of previous that the vaginal gel succeeded at priming uterine receptivity IVF attempts and the duration of treatment were greater-two and maintaining pregnancy even in the complete absence of findings which might have hampered IVF outcome in the endogenous progesterone provided the best possible evidence Crinone group. In the i.m. group, total PR, clinical PR and of product efficacy. live birth rate were 73.9, 60.9 and 50% per embryo transfer It remained important, however, to survey the outcome of respectively. These values are also similar to those appearing regular IVF cycles as well as patient acceptability when luteal in the historical IVF data reported to SART (CDC, 1998) . In support is provided with the vaginal gel. All of the 43 women the Ͻ35 years and the 35-to 39-year-old groups of women, in whom luteal support was initiated with the vaginal gel live birth rates achieved in 1996 were 57.7 and 51.7% per remained on their initially prescribed regimen for their entire embryo transfer respectively. As the objective of the study infertility treatment cycle. The majority of the 13 subjects who was to compare two different forms of luteal support, it had prior experience with i.m. progesterone (69%) preferred appeared sensible to scale all results to the number of embryo Crinone 8% to i.m. injections for several reasons. transfers. Based upon our findings, it is reasonable to conclude
The strength of the present trial evaluating luteal support that luteal support from the vaginal progesterone gel appears from the vaginal progesterone gel resides in the high pregnancy to be as effective as i.m. progesterone, even in IVF programmes rates regularly achieved by the IVF programme that conducted that have ongoing pregnancy rates in excess of 50%.
this testing. In conditions featuring historically high pregnancy In IVF cycles, it is difficult to sort out the respective rates, a possibly inadequate efficacy of luteal support from the roles of exogenous and endogenous progesterone on uterine new vaginal gel presumably would have become more promptly receptivity and pregnancy maintenance. Because of the large apparent. number of functional corpora lutea normally present in IVF Results obtained with the vaginal progesterone gel were cycles, the endogenous production and circulating concentracompared to those seen in a comparably sized group of 46 tions of progesterone commonly exceed menstrual cycle findwomen who underwent IVF during the same period. While ings. Yet, despite the higher progesterone production, a women were not randomly assigned to either i.m. or vaginal meta-analysis confirmed that luteal support improves the outprogesterone, the control group was nonetheless arbitrarily come of IVF cycles in which a GnRH-agonist is used (Soliman et al., 1994) . In this meta-analysis, improvements in pregnancy composed. It consisted of 46 IVF patients not included in the
